Qiagen N.V.

NYSE:QGEN

Medical - Diagnostics & Research

Healthcare
$49.56 -0.96%

-$0.35 today

Market cap
$10.23B
Beta
0.66
P/E (TTM)
18.6
EPS (TTM)
$1.94
Dividend yield
0.69%
52W Low $32.53High $57.82

Volume 4.26M

Average 2.07M

Returns on capital

Qiagen N.V. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

11.2%

avg 7.2%

ROIC

7.8%

avg 4.5%

ROA

6.7%

avg 3.9%

Analysis

ROE is currently the strongest return metric at 11.2% versus its period average of 7.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Thierry Bernard

Member of Management BoardUSD 2.43M62——

Roland Sackers

Chief Financial Officer, MD & Member of Management BoardUSD 1.33M58——

Thomas Theuringer

Senior Director & Head of External Communications————

John Gilardi

Vice President & Head of Corporate Communications————

Jonathan Pratt

CEO & Member of Management Board—56——

Nitin Sood

Senior VP & Head of Product Portfolio & Innovation—53——

Stephany Foster

Senior Vice President & Head of Human Resources—47——

Thomas Schweins

Senior Vice President of Life Science Business Area————

Antonio Santos

Senior Vice President & Head of Global Operations————

Daniel Wendorff CEFA CIIA

VP & Head of Investor Relations————

Jean-Pascal Viola

Senior Vice President & Head of Corporate Strategy and Business Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A-0.2%
+10.1% (5yr)1 analysts
RevenueN/AN/A-0.8%
+4.2% (5yr)6 analysts
Net IncomeN/AN/A+0.1%
+10.0% (5yr)6 analysts
EBITN/AN/A-0.7%
+11.6% (5yr)6 analysts

Analysis

Recent growth has been strongest in Net Income at +0.1% over three years. Forward estimates point to EBIT at +11.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Qiagen N.V. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about QGEN's management, answered from reported figures.

Who manages QGEN?

Qiagen N.V. (QGEN) lists 11 active executives. The top listed executive is Roland Sackers, Chief Financial Officer, MD & Member of Management Board.